CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
Stereotactic Body Radiation Therapy with Integrated Boostradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01856855
NCT01856855N/ACompleted
CompareCT.gov

RAD 1203: Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer

John Fiveash, MD·interventional·Posted May 17, 2013·Updated Jan 12, 2023

In Brief

A clinical study evaluating Stereotactic Body Radiation Therapy with Integrated Boost for Prostate Cancer and 3 related conditions. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This study will investigate the safety, tolerability, and effectiveness of giving a higher dose to the part of the prostate which contains the cancer while giving a standard radiation dose to the entire prostate. The investigators have hypothesized that this treatment technique will effectively control the prostate cancer while minimizing the side effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 17, 2013
Enrollment StartFeb 1, 2013
Primary CompletionDec 1, 2021
Study CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 13.1 years ago

Interventions

Stereotactic Body Radiation Therapy with Integrated Boostradiation

SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions